Literature DB >> 33077624

Regulation of Pulmonary Bacterial Immunity by Follistatin-Like Protein 1.

Matthew Henkel1,2,3, Justin A Dutta1,3,4, Jessica Partyka1,2,3, Taylor Eddens1,2, Raphael Hirsch5,6, Jay K Kolls2,3, Brian T Campfield7,2,3.   

Abstract

Klebsiella pneumoniae is a common cause of antibiotic-resistant pneumonia. Follistatin-like protein 1 (FSTL-1) is highly expressed in the lung and is critical for lung homeostasis. The role of FSTL-1 in immunity to bacterial pneumonia is unknown. Wild-type (WT) and FSTL-1 hypomorphic (Hypo) mice were infected with Klebsiella pneumoniae to determine infectious burden, immune cell abundance, and cytokine production. FSTL-1 Hypo/TCRδ-/- and FSTL-1 Hypo/IL17ra-/- were also generated to assess the role of γδT17 cells in this model. FSTL-1 Hypo mice had reduced K. pneumoniae lung burden compared with that of WT controls. FSTL-1 Hypo mice had increased Il17a/interleukin-17A (IL-17A) and IL-17-dependent cytokine expression. FSTL-1 Hypo lungs also had increased IL-17A+ and TCRγδ+ cells. FSTL-1 Hypo/TCRδ-/- displayed a lung burden similar to that of FSTL-1 Hypo and reduced lung burden compared with the TCRδ-/- controls. However, FSTL-1 Hypo/TCRδ-/- mice had greater bacterial dissemination than FSTL-1 Hypo mice, suggesting that gamma delta T (γδT) cells are dispensable for FSTL-1 Hypo control of pulmonary infection but are required for dissemination control. Confusing these observations, FSTL-1 Hypo/TCRδ-/- lungs had an increased percentage of IL-17A-producing cells compared with that of TCRδ-/- mice. Removal of IL-17A signaling in the FSTL-1 Hypo mouse resulted in an increased lung burden. These findings identify a novel role for FSTL-1 in innate lung immunity to bacterial infection, suggesting that FSTL-1 influences type-17 pulmonary bacterial immunity.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  Klebsiella pneumoniae; follistatin-like 1; interleukin-17; pneumonia

Mesh:

Substances:

Year:  2020        PMID: 33077624      PMCID: PMC7927939          DOI: 10.1128/IAI.00298-20

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  43 in total

1.  Follistatin-like protein 1 is a mesenchyme-derived inflammatory protein and may represent a biomarker for systemic-onset juvenile rheumatoid arthritis.

Authors:  David C Wilson; Anthony D Marinov; Harry C Blair; Daniel S Bushnell; Susan D Thompson; Yury Chaly; Raphael Hirsch
Journal:  Arthritis Rheum       Date:  2010-08

2.  FSTL1 promotes arthritis in mice by enhancing inflammatory cytokine/chemokine expression.

Authors:  Yury Chaly; Anthony D Marinov; Leif Oxburgh; Daniel S Bushnell; Raphael Hirsch
Journal:  Arthritis Rheum       Date:  2011-10-17

3.  Angiocrine FSTL1 (Follistatin-Like Protein 1) Insufficiency Leads to Atrial and Venous Wall Fibrosis via SMAD3 Activation.

Authors:  Haijuan Jiang; Luqing Zhang; Xuelian Liu; Wei Sun; Katsuhiro Kato; Chuankai Chen; Xiao Li; Taotao Li; Zhiliang Sun; Wencan Han; Fujing Zhang; Qi Xiao; Zhongzhou Yang; Junhao Hu; Zhihai Qin; Ralf H Adams; Xiang Gao; Yulong He
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-02-13       Impact factor: 8.311

4.  IL-17 Receptor Signaling in the Lung Epithelium Is Required for Mucosal Chemokine Gradients and Pulmonary Host Defense against K. pneumoniae.

Authors:  Kong Chen; Taylor Eddens; Giraldina Trevejo-Nunez; Emily E Way; Waleed Elsegeiny; David M Ricks; Abhishek V Garg; Carla J Erb; Meihua Bo; Ting Wang; Wei Chen; Janet S Lee; Sarah L Gaffen; Jay K Kolls
Journal:  Cell Host Microbe       Date:  2016-10-27       Impact factor: 21.023

5.  Interleukin-17 and lung host defense against Klebsiella pneumoniae infection.

Authors:  P Ye; P B Garvey; P Zhang; S Nelson; G Bagby; W R Summer; P Schwarzenberger; J E Shellito; J K Kolls
Journal:  Am J Respir Cell Mol Biol       Date:  2001-09       Impact factor: 6.914

6.  Two Types of Interleukin 17A-Producing γδ T Cells in Protection Against Pulmonary Infection With Klebsiella pneumoniae.

Authors:  Tesshin Murakami; Shinya Hatano; Hisakata Yamada; Yoichiro Iwakura; Yasunobu Yoshikai
Journal:  J Infect Dis       Date:  2016-09-20       Impact factor: 5.226

7.  Muscle-derived follistatin-like 1 functions to reduce neointimal formation after vascular injury.

Authors:  Megumi Miyabe; Koji Ohashi; Rei Shibata; Yusuke Uemura; Yasuhiro Ogura; Daisuke Yuasa; Takahiro Kambara; Yoshiyuki Kataoka; Takashi Yamamoto; Kazuhiro Matsuo; Yusuke Joki; Takashi Enomoto; Satoko Hayakawa; Mizuho Hiramatsu-Ito; Masanori Ito; Maurice J B Van Den Hoff; Kenneth Walsh; Toyoaki Murohara; Noriyuki Ouchi
Journal:  Cardiovasc Res       Date:  2014-04-17       Impact factor: 10.787

8.  Blocking the FSTL1-DIP2A Axis Improves Anti-tumor Immunity.

Authors:  Chie Kudo-Saito; Akiko Ishida; Yuji Shouya; Koji Teramoto; Tomoyuki Igarashi; Ryoko Kon; Kenji Saito; Chihiro Awada; Yamato Ogiwara; Masayoshi Toyoura
Journal:  Cell Rep       Date:  2018-08-14       Impact factor: 9.423

9.  The BMP antagonist follistatin-like 1 is required for skeletal and lung organogenesis.

Authors:  Marc Sylva; Vivian S W Li; Anita A A Buffing; Johan H van Es; Maaike van den Born; Saskia van der Velden; Quinn Gunst; Jan Harm Koolstra; Antoon F M Moorman; Hans Clevers; Maurice J B van den Hoff
Journal:  PLoS One       Date:  2011-08-03       Impact factor: 3.240

10.  Blocking follistatin-like 1 attenuates bleomycin-induced pulmonary fibrosis in mice.

Authors:  Yingying Dong; Yan Geng; Lian Li; Xiaohe Li; Xiaohua Yan; Yinshan Fang; Xinxin Li; Siyuan Dong; Xue Liu; Xue Li; Xiuhong Yang; Xiaohong Zheng; Ting Xie; Jiurong Liang; Huaping Dai; Xinqi Liu; Zhinan Yin; Paul W Noble; Dianhua Jiang; Wen Ning
Journal:  J Exp Med       Date:  2015-01-12       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.